



Universiteit  
Leiden  
The Netherlands

## **Immunological aspects of conventional and new treatments for cervical cancer, an immunopharmacological approach**

Meir, H. van

### **Citation**

Meir, H. van. (2017, April 12). *Immunological aspects of conventional and new treatments for cervical cancer, an immunopharmacological approach*. Retrieved from <https://hdl.handle.net/1887/48288>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/48288>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/48288> holds various files of this Leiden University dissertation

**Author:** Meir, H. van

**Title:** Immunological aspects of conventional and new treatments for cervical cancer, an immunopharmacological approach

**Issue Date:** 2017-04-12

IMMUNOLOGICAL ASPECTS OF CONVENTIONAL AND NEW TREATMENTS  
FOR CERVICAL CANCER, AN IMMUNOPHARMACOLOGICAL APPROACH

TO MY PARENTS

TO JORT

**IMMUNOLOGICAL ASPECTS  
OF CONVENTIONAL AND  
NEW TREATMENTS FOR  
CERVICAL CANCER, AN  
IMMUNOPHARMACOLOGICAL  
APPROACH**

PROEFSCHRIFT

ter verkrijging van de graad van Doctor  
aan de Universiteit Leiden, op gezag van  
Rector Magnificus prof. Mr. C.J.J.M. Stolker,  
volgens besluit van het College voor Promoties  
te verdedigen op woensdag 12 april 2017  
klokke 16:15 uur

DOOR

Hélène van Meir  
geboren te Goes in 1981

**PROMOTIECOMMISSIE**

PROMOTORES

Prof. dr. S.H. van der Burg

Prof. dr. J. Burggraaf

Prof. dr. G.G. Kenter (*Center for Gynecologic Oncology Amsterdam*)

CO-PROMOTOR

Dr. M.I.E. van Poelgeest

LEDEN PROMOTIECOMMISSIE

Prof. dr. C.L. Creutzberg

Prof. dr. H.W. Nijman (*University Medical Center Groningen*)

Prof. dr. J.B.A.G. Haanen (*NKI-AVL, Amsterdam*)

The publication of this thesis was financially supported by the foundation  
Centre for Human Drug Research (CHDR) in Leiden, the Netherlands.

DESIGN

Caroline de Lint, Voorburg (caro@delint.nl)

ILLUSTRATION

Leigh Viner

## **GENERAL INTRODUCTION**

- I Prologue: One virus. One disease. Two different clinical outcomes – 7
- II General Introduction – 11

## **PART 1: STANDARD TREATMENT OPTIONS FOR CERVICAL CANCER**

- III The identification of patients at high risk for recurrent disease after treatment for early-stage cervical cancer – 39
- IV The need for improvement of the treatment of advanced and metastatic cervical cancer, the rationale for combined chemo-immunotherapy – 57

## **PART 2: TREATMENTS TO REINFORCE THE IMMUNE SYSTEM**

- V Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T-cell responses – 87
- VI Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients – 135

## **CONCLUSIONS AND DISCUSSION**

- VII Summary, discussion and future perspectives – 173
- VIII Dutch summary – 191

## **APPENDICES**

- Authors and affiliations – 201
- List of abbreviations – 203
- Curriculum Vitae – 205
- List of publications – 206
- Acknowledgments – 208

# **GENERAL INTRODUCTION**